Program
sebetralstat
Also written as “KVD900 600 mg”, “KVD900 300 mg” and “KVD900”.
Its studies are mostly in Angioedemas, Hereditary, led by Chiesi Farmaceutici.
Furthest: phase 4, since Jun 12, 20267 company-led studies, 1 open or runningNext primary completion: Nov 29, 2027 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chiesi Farmaceutici | 71 open or running | phase 4since Jun 12, 2026 | Dec 20, 2019 | Nov 29, 2027phase 4 · NCT07654829 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 20, 2019First study: phase 2 study in Angioedemas, HereditaryFirst studyNCT04208412 · 84 enrolled · United States, Austria, Czechia and more
- Mar 9, 2020Phase 1 study in Angioedemas, HereditaryNCT04349800 · 84 enrolled · United Kingdom
- Feb 4, 2022Phase 3 study in Angioedemas, HereditaryNCT05259917 · 136 enrolled · United States, Australia, Bulgaria and more
- Aug 11, 20222 phase 3 studies in Angioedemas, HereditaryNCT05511922, NCT05505916
- Jun 14, 2024Phase 3 study in Angioedemas, HereditaryNCT06467084 · 36 enrolled · United States, Canada, France and more
- Jun 12, 2026Phase 4 study in Angioedemas, HereditaryNCT07654829 · 100 planned · United States
Ahead
- Nov 29, 2027Primary completion: phase 4 study in Angioedemas, HereditaryNCT07654829
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07654829Angioedemas, Hereditary · United States | 4 | Recruiting | Nov 29, 2027 | 100 |
| NCT06467084Angioedemas, Hereditary · United States, Canada, France and more | 3 | Completed | Jan 15, 2026 | 36 |
| NCT05511922Angioedemas, Hereditary · United States, Australia, Austria and more | 3 | Completed | May 27, 2026 | 11 |
| NCT05505916Angioedemas, Hereditary · United States, Australia, Austria and more | 3 | Completed | May 27, 2026 | 145 |
| NCT05259917Angioedemas, Hereditary · United States, Australia, Bulgaria and more | 3 | Completed | Dec 31, 2023 | 136 |
| NCT04349800Angioedemas, Hereditary · United Kingdom | 1 | Completed | Sep 10, 2018 | 84 |
| NCT04208412Angioedemas, Hereditary · United States, Austria, Czechia and more | 2 | Completed | Dec 8, 2020 | 84 |
How it is read
Names in the registry
- “KVD900 600 mg”, 5 entries
- “KVD900 300 mg”, 3 entries
- “KVD900”, 2 entries
- “KVD900 150 mg”, 1 entry
- “Drug: KVD900 300 mg”, 1 entry
Conditions, from the studies’ own filings
- Angioedemas, Hereditary, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.